Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

By M. McNeil, Stephanie L. Nash, R. Hajjeh, M. Phelan, L. Conn, B. Plikaytis, D. Warnock. Clinical Infectious Diseases, 2001

693 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. (2004, background): “suppressive cancer chemotherapy, especially if this treatment is followed by prolonged periods of neutropenia, such as seen in bone marrow transplantation [1, 2].”
Attributable mortality of nosocomial candidemia, revisited. (2003, background): “In addition, during the 1990s, when prophylaxis for selected high-risk groups began to be implemented more widely, the overall mortality rate attributable to invasive candidiasis decreased [29].”
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007, methodology): “Although there continues to be concern over a perceived increase in both incidence and mortality of IA (43, 44, 51, 85, 132, 149, 154, 194), the overall incidence was almost 10fold lower than that of IC for the years 1996 through 2003 (Table 4).”